Sign In
Buy ALNY
$216.98
-2.22 (-1.01%)
At Close: Aug 10, 2026
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
08:00am, Thursday, 16'th Oct 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter endi
Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals (ALNY) is a Great Choice
01:01pm, Wednesday, 15'th Oct 2025
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?
11:21am, Wednesday, 15'th Oct 2025
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock
10:51am, Tuesday, 14'th Oct 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?
10:41am, Tuesday, 14'th Oct 2025
Here is how Alnylam Pharmaceuticals (ALNY) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
12:05pm, Wednesday, 01'st Oct 2025
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
07:30am, Wednesday, 01'st Oct 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the first patient has been dosed in ZENITH (ZilebEsiraN Car
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new analyses of the HELIOS-B Phase 3 study of AMVUT
Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term
10:51am, Wednesday, 24'th Sep 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 8:00 AM EDT Company Participants Jeffrey Poulton - C
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
09:15am, Thursday, 18'th Sep 2025
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D
Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
05:01pm, Wednesday, 10'th Sep 2025
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 12:20 PM EDT Company Participants Jeffrey Poulton - CFO & Executive VP Conferenc
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?
07:46am, Wednesday, 10'th Sep 2025
Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
11:16pm, Tuesday, 09'th Sep 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
04:15pm, Monday, 08'th Sep 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $500
